GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Bristol Myers Squibb will cut 6% of its workforce in a restructuring meant to save $1.5 billion in costs by the end of next year.
Pfizer Declares Second-Quarter 2024 Dividend
LONDON, April 23 (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Pfizer is letting go an undisclosed number of employees and ending research operations at its site in Boulder, CO, the company confirmed to Endpoints News.
Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Immunology is AbbVie’s world, everyone else just lives in it. That is the takeaway from ZoomRx’s analysis of the perceptions of healthcare professionals (HCPs), who overwhelmingly see AbbVie as the top dog in a field targeted by rivals such as Pfizer and Johnson & Johnson.
As COVID-19 moves into an endemic phase, though rates of coronavirus infections and hospitalizations continue to fall, cases of long COVID appear to be slowly ticking upward. According to data from the U.S. Centers for Disease Control and Prevention, the segment of American adults who have experienced long COVID is now hovering around 17.4%, up from a tally closer to 15% in surveys taken throughout last year.
Connect Biopharma is uncoupling from Pfizer, returning the rights to an eczema candidate it picked up in 2012 to free up cash to advance its two lead programs.